Bridgeway Capital Management’s Standard BioTools LAB Stock Holding History

Bridgeway Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-212,000	Closed	-$575K	–	1307
2024 Q1	$575K	Hold	212,000	–	–	0.01%	887
2023 Q4	$469K	Hold	212,000	–	–	0.01%	954
2023 Q3	$615K	Hold	212,000	–	–	0.01%	826
2023 Q2	$409K	Hold	212,000	–	–	0.01%	961
2023 Q1	$413K	Hold	212,000	–	–	0.01%	929
2022 Q4	$248K	Buy	212,000 +50,000	+31%	+$61.6K	0.01%	1030
2022 Q3	$178K	Buy	+162,000	New	+$245K	﹤0.01%	1160
2019 Q2	–	Sell	-54,945	Closed	-$730K	–	1359
2019 Q1	$730K	Sell	54,945 -113,627	-67%	-$1.2M	0.01%	875
2018 Q4	$1.45M	Hold	168,572	–	–	0.02%	605
2018 Q3	$1.26M	Hold	168,572	–	–	0.01%	784
2018 Q2	$1M	Hold	168,572	–	–	0.01%	875
2018 Q1	$984K	Buy	168,572 +95,000	+129%	+$624K	0.01%	846
2017 Q4	$433K	Sell	73,572 -70,000	-49%	-$383K	﹤0.01%	1140
2017 Q3	$724K	Hold	143,572	–	–	0.01%	968
2017 Q2	$580K	Hold	143,572	–	–	0.01%	1038
2017 Q1	$817K	Buy	+143,572	New	+$910K	0.01%	887

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Bridgeway Capital Management's LAB Position: Q2 2024 in Review

Bridgeway Capital Management sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 212,000 shares — an estimated $575K sold.

Bridgeway Capital Management first reported a position in LAB in Q1 2017 and held it in 16 quarters. The position peaked at $1.45M in Q4 2018. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

Bridgeway Capital Management reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
Bridgeway Capital Management sold 212,000 Standard BioTools shares in Q2 2024, an estimated $575K.
Bridgeway Capital Management first reported a position in Standard BioTools in Q1 2017 and held it in 16 quarters.
Bridgeway Capital Management's Standard BioTools position peaked at $1.45M in Q4 2018.
144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on Bridgeway Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.